Upcoming IPOs
Industry Offer Price Lot Size Entry Fee Offer Period
Listing Date
No company is about to list for the time being.
2023/01/10 15:02
The SW healthcare index (801150.SI) and the Hang Seng healthcare index (HSHCI) retreated 23% and 26%, respectively, in 2022, which was attributable to multiple factors, including rising interest rates, geopolitical tensions and COVID-19 resurgence, UBS reported. Looking ahead to 2023, UBS remained upbeat on the outlook of China&...
2023/01/06 11:07
China National Medical Products Administration (NMPA) expressed that a National Drug Regulation Management work meeting has been convened yesterday (5th), during which several targets for 2023 have been outlined. Specifically, the NMPA pledged to further optimize the COVID-19 vaccine management system and ensure the quality and ...
2022/12/09 09:31
At open, the HSI added 34 pts or 0.2% to 19,484; the HSCEI climbed 8 pts or 0.1% to 6,675; and the HSTECH lifted 8 pts or 0.2% to 4,279. Techs traded mixed. TENCENT (00700.HK) jumped 0.4% to $318.8. BABA-SW (09988.HK) rose 1.4% to $90.65. MEITUAN-W (03690.HK) and BIDU-SW (09888.HK) lost 0.4% and 0.3%. As China reported 58% incre...
2022/12/09 04:29
TRAD CHI MED (00570.HK) noted certain news reports, clarifying that having made such enquiry as is reasonable in the circumstances with Sinopharm Hongkong, the controlling shareholder of the Company, the Company has been informed by Sinopharm Hongkong that as of the date of this announcement, CNPGC, after its preliminary conside...
2022/12/08 18:25
There was HKD502.8 million, HKD289.1 million and HKD255.5 million Southbound Trading net inflow to TENCENT (00700.HK), XPENG-W (09868.HK) and KUAISHOU-W (01024.HK).There was HKD131 million and HKD111.5 million Southbound Trading net outflow from TRAD CHI MED (00570.HK) and WUXI BIO (02269.HK).For Southbound Trading of Shanghai-H...
2022/12/08 09:39
TRAD CHI MED (00570.HK) opened up 14.85% today (8th), peaking at $4.82. It last printed at $4.39, up 16.45%, on volume of 82.6 million shares and turnover of $371.53 million.SINOPHARM is reconsidering privatization of TRAD CHI MED at US$4 billion valuation, wire cited people with the knowledge of the matter. The privatization pr...
2022/12/07 17:25
China National Pharmaceutical Group Co. (Sinopharm) is reconsidering a potential privatization of TRAD CHI MED (00570.HK) in a deal that could value the latter at USD4 billion, Bloomberg News cited people with knowledge of the matter. Specifically, Sinopharm and its advisers are evaluating an offer of about $6 for each TRAD CHI ...
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
You expressly agree that the use of this app/website is at your sole risk. Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party. Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account. Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance. Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor. Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance. Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.